Standard BioTools Inc. Retained Earnings
Standard BioTools Inc. (LAB) had Retained Earnings of -$1.16 billion as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-05
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$1.16B.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$1.13B.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$1.26B.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$1.28B.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$1.16B 10-Q · filed 2026-08-05 |
| 2026-03-31 | -$1.13B 10-Q · filed 2026-05-06 |
| 2025-12-31 | -$1.26B 10-Q · filed 2026-08-05 |
| 2025-09-30 | -$1.28B 10-Q · filed 2025-11-04 |
| 2025-06-30 | -$1.25B 10-Q · filed 2025-08-15 |
| 2025-03-31 | -$1.21B 10-Q · filed 2025-05-06 |
| 2024-12-31 | -$1.19B 10-K · filed 2026-03-16 |
| 2024-09-30 | -$1.15B 10-Q · filed 2024-11-06 |
| 2024-06-30 | -$1.12B 10-Q · filed 2024-08-06 |
| 2024-03-31 | -$1.08B 10-Q · filed 2024-05-09 |
| 2023-12-31 | -$1.00B 10-K · filed 2025-03-11 |
| 2023-09-30 | -$980.98M 10-Q · filed 2023-11-07 |
| 2023-06-30 | -$959.98M 10-Q · filed 2023-08-08 |
| 2023-03-31 | -$942.94M 10-Q · filed 2023-05-09 |
| 2022-12-31 | -$926.10M 10-K · filed 2024-03-01 |
| 2022-09-30 | -$905.25M 10-Q · filed 2022-11-09 |
| 2022-06-30 | -$875.83M 10-Q · filed 2022-08-09 |
| 2022-03-31 | -$812.29M 10-Q · filed 2022-05-09 |
| 2021-12-31 | -$736.00M 10-K · filed 2023-03-14 |
| 2021-09-30 | -$726.57M 10-Q · filed 2021-11-09 |
| 2021-06-30 | -$712.73M 10-Q · filed 2021-08-06 |
| 2021-03-31 | -$695.58M 10-Q · filed 2021-05-07 |
| 2020-12-31 | -$676.76M 10-K · filed 2022-03-08 |
| 2020-09-30 | -$658.74M 10-Q · filed 2020-11-09 |
| 2020-06-30 | -$652.74M 10-Q · filed 2020-08-07 |
| 2020-03-31 | -$639.72M 10-Q · filed 2020-05-11 |
| 2019-12-31 | -$623.64M 10-K · filed 2021-02-25 |
| 2019-09-30 | -$610.96M 10-Q · filed 2019-11-08 |
| 2019-06-30 | -$598.07M 10-Q · filed 2019-08-07 |
| 2019-03-31 | -$584.32M 10-Q · filed 2019-05-07 |
| 2018-12-31 | -$558.85M 10-K · filed 2020-02-27 |
| 2018-09-30 | -$544.08M 10-Q · filed 2018-11-06 |
| 2018-06-30 | -$529.33M 10-Q · filed 2018-08-08 |
| 2018-03-31 | -$513.08M 10-Q · filed 2018-05-08 |
| 2018-01-01 | -$499.84M 10-K · filed 2019-03-18 |
| 2017-12-31 | -$500.20M 10-K · filed 2019-03-18 |
| 2017-09-30 | -$489.74M 10-Q · filed 2017-11-07 |
| 2017-06-30 | -$473.80M 10-Q · filed 2017-08-08 |
| 2017-03-31 | -$456.86M 10-Q · filed 2017-05-09 |
| 2016-12-31 | -$439.48M 10-K · filed 2018-03-08 |
| 2016-09-30 | -$421.78M 10-Q · filed 2016-11-09 |
| 2016-06-30 | -$401.99M 10-Q · filed 2016-08-09 |
| 2016-03-31 | -$383.38M 10-Q · filed 2016-05-09 |
| 2015-12-31 | -$363.49M 10-K · filed 2017-03-03 |
| 2015-09-30 | -$350.61M 10-Q · filed 2015-11-09 |
| 2015-06-30 | -$341.34M 10-Q · filed 2015-08-10 |
| 2015-03-31 | -$326.11M 10-Q · filed 2015-05-11 |
| 2014-12-31 | -$310.18M 10-K · filed 2016-02-29 |
| 2014-09-30 | -$299.23M 10-Q · filed 2014-11-06 |
| 2014-06-30 | -$285.44M 10-Q · filed 2014-08-04 |
| 2014-03-31 | -$272.76M 10-Q · filed 2014-05-12 |
| 2013-12-31 | -$257.35M 10-K · filed 2015-02-26 |
| 2013-09-30 | -$252.70M 10-Q · filed 2013-11-07 |
| 2013-06-30 | -$248.42M 10-Q · filed 2013-08-07 |
| 2013-03-31 | -$244.37M 10-Q · filed 2013-05-09 |
| 2012-12-31 | -$240.82M 10-K · filed 2014-03-12 |
| 2012-09-30 | -$237.22M 10-Q · filed 2012-11-09 |
| 2012-06-30 | -$233.07M 10-Q · filed 2012-08-14 |
| 2012-03-31 | -$228.49M 10-Q · filed 2012-05-15 |
| 2011-12-31 | -$221.80M 10-K · filed 2013-03-12 |
| 2011-09-30 | -$218.34M 10-Q · filed 2011-11-14 |
| 2011-06-30 | -$213.85M 10-Q · filed 2011-08-09 |
| 2010-12-31 | -$199.33M 10-K · filed 2012-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |